Whitehawk Therapeutics (NASDAQ:WHWK) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) issued its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10, Zacks reports.

Whitehawk Therapeutics Stock Up 15.5%

Shares of Whitehawk Therapeutics stock traded up $0.63 during trading on Thursday, reaching $4.70. 308,563 shares of the stock were exchanged, compared to its average volume of 431,950. The firm has a market cap of $232.41 million, a price-to-earnings ratio of -2.80 and a beta of 0.76. Whitehawk Therapeutics has a 1 year low of $1.57 and a 1 year high of $5.49. The stock’s fifty day moving average is $4.11 and its 200 day moving average is $3.78.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on WHWK shares. Leerink Partners started coverage on Whitehawk Therapeutics in a research note on Monday, July 13th. They set an “outperform” rating and a $9.00 price objective on the stock. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. B. Riley Financial assumed coverage on Whitehawk Therapeutics in a research note on Thursday, June 25th. They issued a “buy” rating and a $10.00 price target on the stock. Citizens Jmp assumed coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 price objective for the company. Finally, Weiss Ratings lowered Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of WHWK. State Street Corp lifted its stake in Whitehawk Therapeutics by 111.7% in the fourth quarter. State Street Corp now owns 145,537 shares of the company’s stock worth $352,000 after acquiring an additional 76,800 shares during the period. Geode Capital Management LLC increased its stake in shares of Whitehawk Therapeutics by 11.4% during the fourth quarter. Geode Capital Management LLC now owns 425,440 shares of the company’s stock valued at $1,030,000 after purchasing an additional 43,686 shares in the last quarter. Acorn Capital Advisors LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $2,165,000. Yu Fan bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $3,933,000. Finally, Citadel Advisors LLC bought a new position in shares of Whitehawk Therapeutics in the third quarter worth approximately $266,000. Institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.